Vital Therapies, Inc. (VTL)

[joezapp]

There is a statistically significant subset that is being tried with the FDA's blessing. The subset is subjects under age 50 with some liver damage. The subject cannot have extreme liver damage, and cannot be elderly, as in each case developing new liver cells quickly enough has proven difficult.

The FDA gave the go-ahead, albeit under their terms. There was a heavy insider buy over $9. I like the odds. We're all playing with fire, but you more so. If this succeeds, the stock will fly over 30. If it doesn't, it goes to near zero. I maintain fair value right now is 12, with a max in the 13-15 range through early 2016 while we wait for the news.